FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to experimental virology, and can be used to inhibit infectious activity of Ebola virus in experiment. Method involves introduction to Guinea pigs preparation of recombinant human interferon alpha-2 before or during penetration agent in animal's body in daily dose sufficient for developing antiviral agent inhibiting activity. For this purpose, preparation “Reaferon-Lipint” in liposomal form is used in daily dose from 200,000 to 300,000 IU/kg. When simulating prevention and treatment of viral infection this preparation is introduced for 12 and 1 hours to virus infection inoculation of Ebola virus, at moment of infection and through 12, 24, 36, 48, 60, 72 hours after infection of Ebola virus.
EFFECT: method provides achievement of inhibitory effect at reduction of preventive and therapeutic dose of recombinant human interferon alpha-2.
2 cl, 3 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR BODY PROTECTION AGAINST INFECTION CAUSED BY INFLUENZA A VIRUS SUBTYPE H1N1 STRAINS WITH PREPARATION OF HUMAN ALPHA-2 INTERFERON | 2013 |
|
RU2523554C1 |
| METHOD OF PROPHYLAXIS OF VIRAL AEROGENIC INFECTIONS | 1995 |
|
RU2105565C1 |
| METHOD OF PREVENTING DISEASE CAUSED BY AVIAN FLU VIRUS | 2008 |
|
RU2395295C2 |
| METHOD OF TREATING CHRONIC VIRAL HEPATITIS C WITH MEDICATIONS IN LIPOSOMAL FORM | 2011 |
|
RU2475263C1 |
| STRAIN A/Salekhard/01/2009(H1N1)v OF SUBTYPE H1N1 INFLUENZA A VIRUS FOR STUDYING THERAPEUTIC AND PROPHYLACTIC EFFICACY OF PREPARATIONS FOR INFLUENZA VIRUS | 2011 |
|
RU2457242C1 |
| METHOD OF TREATING TICK-BORNE ENCEPHALITIS | 2011 |
|
RU2473364C2 |
| STRAIN OF EBOL VIRUS "ZAIR K-5" FOR CARRYING OUT MODEL EXPERIMENTS AND PREPARING DIAGNOSTIC AND VACCINE PREPARATIONS | 2001 |
|
RU2225439C2 |
| ANTI-ENTEROVIRAL AND IMMUNOSTIMULATING AGENT | 2014 |
|
RU2554761C1 |
| METHOD FOR TREATING ACUTE HEPRETIC STOMATITIS IN CHILDREN | 2011 |
|
RU2444372C1 |
| STRAIN C/2014 OF MACHUPO VIRUS - AGENT OF BOLIVIAN HAEMORRHAGIC FEVER INTENDED FOR LABORATORY EVALUATION OF EFFECTIVENESS OF MEDICAL REMEDIES IN RESPECT OF THIS PATHOGEN | 2017 |
|
RU2699525C2 |
